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Demam kepialu disebabkan oleh Salmonella enterica subspesies enterica 
serovar Typhi (S. Typhi). Penyakit sistemik akut ini kekal sebagai satu masalah 
kesihatan awam yang utama di seluruh dunia. Kekurangan penanda diagnostik yang 
spesifik dan sensitif untuk pengesanan S. Typhi pada resolusi sasaran gen tunggal 
menghalang usaha pengawalan penyakit yang cekap. Dalam fasa pertama kajian ini, 
perbandingan genomik bagi S. Typhi dengan patogen enteric lain dilakukan dengan 
menggunakan BLASTn. Enam gen iaitu STY0201, STY0307, STY0322, STY0326, 
STY2020 dan STY2021 didapati spesifik dan sensitif in silico. Enam ujian PCR 
sasaran gen tunggal telah dibangunkan dengan kawalan amplifikasi dalaman dan 
dioptimakan dengan menggunakan kaedah Taguchi. Spesifisiti analisa bagi ujian PCR 
yang dioptimakan telah ditentukan dengan menggunakan DNA tulen yang diperolehi 
daripada 39 S. Typhi, 62 Salmonella bukan-Typhi dan 10 bukan-Salmonella strain 
klinikal. Sensitiviti analisa bagi ujian PCR yang dioptimakan telah ditentukan dengan 
menggunakan pencairan 5-ganda genomik DNA dan pencairan 10-ganda bakteria 
kultur. Ujian-ujian penilaian ke atas spesifisiti diagnostik dan sensitiviti diagnostik 
telah diuji dengan lebih lanjut untuk salah satu daripada ujian yang paling spesifik dan 
sensitif. Daripada 6 calon gen, 5 gen iaitu STY0307, STY0322, STY0326, STY2020 
dan STY2021 menunjukkan 100% spesifisiti analitikal (pengesanan 39/39 strain 
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bakteria). Gen STY0201 menunjukkan 97.2% spesifisiti analitikal (pengesanan 70/72 
strain bakteria). Sensitiviti 6 ujian PCR dengan DNA genom ialah; 32 pg untuk 
STY0322, 6.4 pg untuk STY0201, STY0326, STY2020 dan STY2021, dan 1.28 pg 
untuk STY0307. Sensitiviti ujian PCR dalam kiraan bakteria ialah seperti yang berikut; 
1.5 × 105 cfu/mL untuk STY0307; 1.5 × 106 cfu/mL untuk STY0201, STY0322, 
STY0326, STY2020 dan STY2021. Ujian PCR STY0307 menunjukkan sensitiviti 
yang paling tinggi. Oleh itu, ia telah dipilih untuk penilaian lanjut dengan 
menggunakan sampel tinja yang dicemari bakteria. Dengan pengeraman selama 18 
jam, sensitiviti ujian PCR STY0307 ialah 1.5 × 104 cfu/mL. Ujian PCR STY0307 
menunjukkan 100% spesifisiti dan sensitiviti diagnostik apabila dilakukan secara 
rawak buta terhadap 130 sampel klinikal. Fasa kedua kajian ini telah dicadangkan 
untuk mengkaji nilai keantigenan protein-protein yang dikodkan oleh gen-gen yang 
dikenal pasti dalam fasa pertama kajian ini. Analisis bioinformatik telah digunakan 
untuk meramal potensi calon-calon antigen. Berdasarkan rasional skor ramalan 
keantigenan dan spesifisiti yang tinggi, 3 gen S. Typhi iaitu STY0307, STY0326 dan 
STY2020 telah dipilih untuk produksi protein dengan menggunakan teknik DNA 
rekombinan. Keantigenan protein yang afiniti-ditulenkan telah diuji menggunakan 
ELISAs tidak langsung, terhadap 12 sera demam kepialu, 28 sera bukan demam 
kepialu dan 28 sera sihat. Daripada 3 calon protein yang dikaji, 2 protein, STY0307 
dan STY2020 menunjukkan tindak balas dengan IgM, IgG dan IgA antibodi daripada 
serum demam kepialu berbanding dengan serum bukan demam kepialu dan serum 
sihat (p<0.01). Anti-STY0307 ELISA mencapai 91.7% sensitiviti (11/12) dan 92.9% 
spesifisiti (52/56), manakala anti-STY2020 ELISA menunjukkan 66.7% sensitiviti 
(8/12) dan 94.6% spesifisiti (53/56). Anti-STY0326 ELISA mencapai hanya 25.0% 
sensitiviti (3/12) dengan 96.4% spesifisiti (54/56). Kesimpulannya, 5 gen iaitu 
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STY0307, STY0322, STY0326, STY2020 dan STY2021 telah didapati 100% spesifik 
dan 100% sensitif sebagai penanda DNA untuk identifikasi S. Typhi. Dua gen, 
STY0307 dan STY2020 bukan sahaja sesuai sebagai penanda diagnostik DNA yang 
spesifik dan sensitif, tetapi protein yang diekspreskan juga berguna sebagai penanda 
sero-diagnostik. Hasil kajian ini menjamin pembangunan diagnostik yang 
dipertambahbaikan dan pembangunan vaksin untuk demam kepialu.  
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IDENTIFICATION OF Salmonella enterica subspecies enterica serovar Typhi-
SPECIFIC GENES FOR THE DEVELOPMENT OF DNA-BASED AND 
ANTIBODY-BASED DIAGNOSTICS FOR TYPHOID FEVER 
 
ABSTRACT 
Typhoid fever is caused by Salmonella enterica subspecies enterica serovar Typhi 
(S. Typhi). It is an acute systemic disease which remains a major public health burden 
worldwide. A lack of specific and sensitive diagnostic markers for detection of S. Typhi 
at single-gene target resolution prevents effective diagnosis and therefore efficient 
control of the disease. In the first phase of this study, genome level comparison of S. 
Typhi with other enteric pathogens was performed using BLASTn. Six genes, i.e. 
STY0201, STY0307, STY0322, STY0326, STY2020 and STY2021 were found to be 
specific and sensitive in silico. Six individual single-gene target PCR assays with the 
incorporation of an internal amplification control (IAC) were developed and optimised 
using Taguchi method. The analytical specificities of the optimised PCR assays were 
determined using purified DNA from 39 S. Typhi, 62 non-Typhi Salmonella, and 10 
non-Salmonella clinical strains. The analytical sensitivities of the PCR assays were 
assessed using 5-fold dilutions of genomic DNA and 10-fold dilutions of bacterial 
culture. Diagnostic specificity and diagnostic sensitivity evaluation tests were further 
assessed for one of these highly sensitive and specific assays. Of the 6 candidate genes, 
5 genes i.e. STY0307, STY0322, STY0326, STY2020 and STY2021 demonstrated 
100% analytical specificity (detection of 39/39 bacteria strains). Gene STY0201 
demonstrated 97.2% analytical specificity (detection of 70/72 bacteria strains). The 
sensitivities of the 6 PCR assays by genomic DNA were; 32 pg for STY0322, 6.4 pg 
for STY0201, STY0326, STY2020 and STY2021, and 1.28 pg for STY0307. The 
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sensitivities of these PCR assays by bacteria counts were as follows; 1.5 × 105 cfu/mL 
for STY0307 and 1.5 × 106 cfu/mL for STY0201, STY0322, STY0326, STY2020 and 
STY2021. Since the STY0307 PCR assay demonstrated the highest analytical 
sensitivity, it was selected for further sensitivity evaluation using spiked stool samples. 
It was found that with 18 hr enrichment, the sensitivity of STY0307 PCR assay was 
1.5 × 104 cfu/mL. The STY0307 PCR assay demonstrated 100% diagnostic specificity 
and sensitivity when 130 clinical samples were blind screened. The second phase of 
this study was carried out in order to study the antigenicity of the proteins encoded by 
the genes identified in the first phase of this study. Bioinformatics analysis was used 
to predict the potential antigen candidates. Based on a rationale of high antigenicity 
and high specificity prediction scores, 3 S. Typhi genes, i.e. STY0307, STY0326 and 
STY2020, were selected for cloning and protein expression using recombinant DNA 
techniques. The antigenicity of the affinity-purified proteins was evaluated using 
indirect ELISAs against 12 typhoid fever, 28 non-typhoid fever and 28 healthy sera. 
Of the 3 candidate proteins investigated, 2 proteins, STY0307 and STY2020 showed 
reactivity with IgM, IgG and IgA antibodies from typhoid patient sera compared to the 
non-typhoid and healthy control sera (p<0.01).  The anti-STY0307 ELISA achieved 
91.7% sensitivity (11/12) and 92.9% specificity (52/56), whereas the anti-STY2020 
ELISA demonstrated 66.7% sensitivity (8/12) and 94.6% specificity (53/56). Anti-
STY0326 ELISA achieved only 25.0% sensitivity (3/12) and 96.4% specificity (54/56). 
In conclusion, 5 genes namely, STY0307, STY0322, STY0326, STY2020 and 
STY2021, were found to be 100% specific and 100% sensitive as DNA markers for S. 
Typhi identification. Two of the genes, STY0307 and STY2020 not only could serve 
as sensitive and specific DNA diagnostic markers, but their corresponding proteins 
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were shown to be sero-diagnostically useful as well. These results hold promise for the 
development of improved diagnostics and vaccine for typhoid fever. 
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1.1 Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) 
Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) is a Gram-negative, 
non-spore forming, facultative anaerobic bacteria that belongs to the family of 
Enterobacteriaceae. It is rod-shaped, 0.7-1.5 × 2.0-5.0 µm in size, and flagellated 
(Figure 1.1). Unlike other Salmonella serovars, S. Typhi causes typhoid fever, an acute 
systemic disease that is exclusive to humans. It is exquisitely adapted to the human gut 
before invading the bloodstream via the Peyer’s patches in the small intestine 
(Raffatellu et al., 2008), and causing gastrointestinal inflammation and high fever for 
extended periods of time. Worldwide, there are approximately 26.9 million typhoid 
cases and 269,000 deaths each year (Buckle et al., 2012). Inadequate sanitation and 
sewage disposable systems, contaminated water supplies and poor personal hygiene, 
provide an opportunity for this pathogen to infect and colonise humans, leading to 
substantial illness, mortality and enormous financial loss (Dewan et al., 2013). Correct 
diagnosis is essential for effective clinical management to reduce the morbidity and 
mortality rates. Yet, reliable diagnostic markers and tests remain tragically elusive. 
Without correct diagnosis and effective treatment, typhoid fever may progress to more 
severe illness, such as peritonitis, intestinal haemorrhage or perforation, exacerbating 
the case-fatality rates to 10-30% (Buckle et al., 2012).  
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Figure 1.1 An electron microscope image of S. Typhi showing flagella and short 
fimbriae (Adapted from https://www.britannica.com/science) 
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1.1.1 Taxonomy 
According to Le Minor and Popoff in 1987, the species Salmonella enterica could be 
classified into 7 subspecies, namely; I, enterica; II, salamae; IIIa, arizonae; IIIb, 
diarizonae; IV, houtenae; V, bongori; and VI, indica (Le Minor & Popoff, 1987). S. 
bongori was later re-classified as a distinct species based on DNA-DNA hybridization 
studies (Agbaje et al., 2011). In 2005, a new Salmonella species, Salmonella 
subterranean was identified (Su & Chiu, 2006). Today, it is generally accepted that 
the genus Salmonella consists of 3 species (Salmonella enterica, Salmonella bongori 
and Salmonella subterranean), 6 subspecies (S. enterica subsp. enterica, S. enterica 
subsp. salamae, S. enterica subsp. arizonae, S. enterica subsp. diarizonae, S. enterica 
subsp. houtenae and S. enterica subsp. indica), and 2,659 serotypes (Issenhuth-
Jeanjean et al., 2014) (Table 1.1). S. Typhi is a serotype that belongs to S. enterica 
subspecies I (S. enterica subsp. enterica). 
 
1.1.2 Nomenclature 
Salmonella nomenclature is complex and has long been an issue of discussion. In the 
early 1920s, the taxonomy of Salmonella was in confusion until the development of 
the Kauffman-White scheme by Philip Bruce White in 1926. This scheme was then 
expanded by Fritz Kauffman from 1933-1978 (Hardy, 2004). The Kauffman-White 
scheme classified Salmonella species based on serological identification of O 
(somatic) and H (flagella) antigens, resulting in assignment of isolates to more than 
2,500 serovars today. Many new serovars continue to be discovered each year. 
Currently, the Salmonella nomenclature system is maintained by the World Health 
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Organization (WHO) Collaborating Centre for Reference and Research on Salmonella 
at the Pasteur Institute, France (Agbaje et al., 2011). 
 
When cited at the first time in a report, the genus name is italic and followed by the 
species (italic), subspecies (italic) and lastly the serotype name (non-italicized roman 
letters and starts with a capital letter) (Issenhuth-Jeanjean et al., 2014), e.g. Salmonella 
enterica subspecies enterica serotype Typhi. This can also be stated as Salmonella ser. 
Typhi or simply Salmonella Typhi (S. Typhi). Since it is in subspecies I under 
serogroup D with the presence of O-9, O-12, Vi polysaccharides and phase 1 d-H 
antigens, S. Typhi can be named as Salmonella subspecies I, 9, 12, Vi:d. The details 
of Salmonella taxonomy and nomenclature is as shown in Table 1.1. 
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Table 1.1 Taxonomy and Nomenclature of Salmonella (Issenhuth-Jeanjean et al., 
2014) 
 





























(or subspecies II) 
9, 46:z:z39 522 
 
arizonae  




(or subspecies IIIb) 
6,7:1, v:1,5,7 338 
 
houtenae  
(or subspecies IV) 
21:m, t:- 76 
 
indica  
(or subspecies VI) 
59:z36:- 13 
 bongori subspecies V 13,22:z39:- 22 
 subterranea    
Total 2,659 
*some selected serovars (serotypes) are listed as examples  
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1.2 Typhoid fever 
S. Typhi infection leads to the development of enteric fever, or more commonly known 
as typhoid fever. It is a systemic infection of the intestinal lymphoid tissue, gallbladder 
and the reticulo-endothelial system. The name “typhoid” was derived from the word 
“typhus”, owing to the indistinguishable clinical manifestations with the disease called 
typhus caused by Rickettsia bacteria. The burden of typhoid fever lies most critical in 
under-developed and developing countries, facilitated by inadequate personal hygiene, 
water supplies and sanitary systems. This disease is characterised by the sudden onset 
of a sustained high fever, constipation or diarrhea, malaise and abdominal pain 
(Gonzalez-escobedo et al., 2011). Serious complications, such as intestinal perforation 
and septicaemia could occur leading to high mortality (Gonzalez-escobedo et al., 
2011).  The disease affects all age groups, with higher incidence found in children 
(Darton et al., 2014), immuno-compromised persons, and the elderly (Dougan, 2017).  
Complete control and eradication of typhoid fever remains a challenge despite 
improved sewage systems, socio-economic well-being and extensive efforts in public 
health. To further worsen the scenario, multidrug-resistant strains, which are 
responsible for high mortality, have risen over the past decade and appeared to be 
spreading worldwide (Wong et al., 2015) 
 
1.2.1 Epidemiology 
According to an epidemiological study in 2000, there were 21.6 million cases and 
216,000 deaths each year (Crump et al., 2004). An updated study by Buckle et al. in 
2012 indicated that typhoid fever accounted for 26.9 million cases and 269,000 deaths 
each year. The true incidence of the disease burden is probably higher due to a lack of 
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reliable data collection systems in many endemic regions (Crump, 2014), especially in 
Latin America and Africa (Buckle et al., 2012). The paucity of information regarding 
the true burden of the disease makes it a truly neglected disease. 
 
Typhoid fever is a plague of the poor. It usually occurs in low and middle-income 
countries (Buckle et al., 2012). Regions of high incidence (>100/100,000 cases/year) 
include South-central Asia and Southeast Asia (Crump et al., 2004). Three countries, 
namely, India, Bangladesh and Pakistan together account for approximately 85% of 
the world’s typhoid cases (Maurice, 2012). Medium incidence regions (10-
100/100,000 population/year) include the rest of Asia, Latin America, Africa, the 
Caribbean, and Oceania, except New Zealand and Australia. Regions of low incidence 
rates (<10/100,000 population/year) include North America and other developed 
countries (Crump et al., 2004). The low typhoid incidence rate in the developed 
countries could be associated with improved patient care, water sewage system and 
personal hygiene. However, sporadic outbreaks do occur in developed countries with 
most cases amongst travellers who had returned from typhoid endemic areas. In the 
US, about 80% of cases in the country occur from returned travellers and immigrants 
(Basnyat et al., 2005; Lynch et al., 2009). Judged by the association between migration 
and introduction of disease in this interconnected world, a history of travel to typhoid-
endemic countries is useful for determining people who are at risk of the infection. 
 
Malaysia is one of the countries in Southeast Asia which is endemic for typhoid fever 
(Figure 1.2). Presently, typhoid fever in Malaysia is considered sporadic with 
occasional outbreaks confined to a few areas where safe water supply, sanitation, food-
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handling and personal hygiene practices are inadequate. The highest incidence rate in 
the country occurred in 2005 with 4.1 cases per 100,000 population (Figure 1.3).  One 
state hit hard was Kelantan. In 2005, several outbreaks of typhoid fever occurred in 
the state, resulting in a high incidence rate of 56.7 per 100,000 population in which 
735 culture-confirmed cases and 2 deaths were reported (Baddam et al., 2012). Several 
intervention programs, such as food premise grading system, law regarding food 
hygiene, food premise inspection, and improved water supply, have been implemented 
by the government and the state Public Health Department. As a consequence of these 
interventions and government prodding, the incidence rate of typhoid fever in 
Malaysia in the past 10 years has decreased to 1.42 per 100,000 population in 2015 
(Figure 1.3). 
 
S. Typhi is a bacterium that can live in water and soil for several months and then, 
when scuffed out, infects humans. It is common to see the rise of typhoid fever cases 
during natural disasters such as floods, tsunamis, and earthquakes (Sutiono et al., 
2010). Seasonal variation (45% of reported cases) was observed and associated with 
the monsoon season (July to October) in Southeast Asia. 
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Figure 1.2 Global distribution of typhoid fever (Adapted from Crump et al., 2004)  
 
Figure 1.3 Incidence rate of typhoid fever per 100,000 population in Malaysia 































Incidence Rate of Typhoid Fever in Malaysia
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1.2.2 Pathogenesis 
The pathogenesis of typhoid fever is difficult to study as humans are the only reservoir 
for the disease and there is no animal model. Current understanding of S. Typhi 
pathogenesis has been gleaned from the study of S. Typhimurium-infected murine 
model, which exhibits disseminate systemic infection with some resemble to that of 
human typhoid (Salazar et al., 2017). 
 
The infection starts with the ingestion of food or water contaminated with S. Typhi 
(approximately 103-106 cfu/mL) into the human alimentary canal (Ja’afar et al., 2013). 
S. Typhi is able to survive the destructive effects of gastric acid and the stomach 
barrier, and reach the small intestine. The intestinal wall is mainly made up of 
epithelial cells which serve as a protective layer against harmful substances. To invade 
the mucosa barrier of the small intestine, S. Typhi employs specialised fimbriae that 
help it to adhere to the epithelium of the Peyer’s patches, usually the M cells (Kaur & 
Jain, 2012). A complex attack system, the type III secretion system (T3SS) of the 
bacteria is employed to initiate bacterial endocytosis. S. Typhi injects the effectors into 
the intestinal cell and causes host cell membrane ruffling to engulf the bacilli in an 
intracellular vacuole. However, S. Typhi is able to escape the intracellular vacuole and 
reach the lymphoid follicles at the Peyer’s patches. They are then transported to the 
mesenteric lymph nodes, formed mainly by mononuclear cells such as T lymphocytes, 
as well as dendritic cells (De Andrade & De Andrade, 2003), and provoke cell-
mediated and humoral responses. 
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S. Typhi is then phagocytised by macrophages. The Vi capsular polysaccharide 
prevents recognition by the pattern recognition receptors (PRRs) and enables S. Typhi 
to travel within the host’s circulating system undetected by the host immune system 
(Wilson et al., 2008). Survival from the phagolysosome process of the macrophage 
cells and even replicating within the macrophage cell, enables S. Typhi to be carried 
through the mesenteric lymph nodes and to the reticuloendothelial system, such as 
bone marrow, lymph nodes, spleen and liver (Garai et al., 2012). This primary 
bacteraemia stage is usually symptomless, and the blood culture is usually negative. 
 
Secondary bacteraemia happens when S. Typhi continues to multiply and induce 
macrophage apoptosis, breaking out into the bloodstream. The organism re-enters the 
gastrointestinal tract in the bile and re-infects the Peyer’s patches. They may 
eventually spread to the gallbladder via either vasculature or ducts from the liver.  The 
bacteria is then excreted from the faeces, and transmission to other individuals via 
contamination of water and food. This secondary bacteraemia coincides with the onset 
of typhoid symptoms and marks the end of the incubation period (WHO, 2003). 
 
1.2.3 Immune Response 
Typhoid infection is restricted to humans. Therefore, the molecular pathogenesis of 
the pathogen must be unique and the host’s immune response specific. The complex 
immune response to S. Typhi involves both innate and adaptive immune systems. 
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1.2.3 (a) Innate Immune System (Non-specific Immune System) 
The innate immune system provides immediate first line host defense against the 
invading pathogens. Gastric acidity (pH<3.5) serves as the first line of host defence 
against S. Typhi infection as it is ingested with water and food. However, S. Typhi 
manages to survive low pH gastric acid and encounter the next barrier - intestinal 
mucosa layer. Mucus covers the surface of the gut epithelium lining and acts as a 
protective layer to prevent direct contact of harmful bacteria with the epithelium. 
During S. Typhi infection, M cells in the epithelium are employed by S. Typhi as a 
means of transportation to the lumen epithelium and reach the lamina propria. 
Following this epithelial invasion, the presence of S. Typhi is detected by monocyte-
derived phagocytic cells, namely macrophages and dendritic cells. These cells express 
a large family of pattern recognition receptors (PRRs) on their surfaces which detect 
pathogen-associated-molecular-patterns (PAMPs) and danger-associated-molecular-
patterns (DAMPs) on pathogens. PAMPs expressed by S. Typhi include flagella, 
fimbria, T3SS protein, lipopolysaccharide and bacterial DNA (de Jong et al., 2012). 
Upon engagement with PAMPs and DAMPs, the PRRs trigger expression of soluble 
protein called cytokines, leading to the activation of the adaptive immune system 
(Raffatellu et al., 2006). 
 
1.2.3 (b) Adaptive Immune System (Specific Immune System) 
When the innate immune response fails to prevent the entrance of S. Typhi, the 
adaptive immune system comes into play with the help of T and B cells. The adaptive 
immunity appears slowly, but it is more specialised and potent. Adaptive immune 
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system consists of cellular and humoral components which help them to carry out their 
protective functions. 
 
1.2.3 (bi) Cellular Immune Response 
The cellular immune response (CRI) or cell-mediated immunity (CMI) represents the 
cellular component of the immune response and plays a dominant role in the early 
response to S. Typhi infection since S. Typhi could persist intracellularly. Two major 
components, CD4+ and CD8+ cytotoxic T-cells are involved in CMI of typhoid 
infection (Lundin et al., 2002).  The recognition of  CD4+ and CD8+ T cells against 
the S. Typhi antigens leads to secretion of pro-inflammatory cytokines, such as 
interferon (IFN)-γ, interleukin (IL)-6, IL-8 and Tumor Necrosis Factor (TNF)-α 
(Fiorentino et al., 2013). The predominant cytokine, IFN-γ enhances the phagocytic 
ability of the macrophages (Nairz et al., 2008). However, with T3SS mechanisms, S. 
Typhi can survive and use the macrophages as a vector for transport into the 
reticuloendothelial system of the host, such as bone marrow, lymph nodes, spleen and 
liver (Dougan & Baker, 2014). S. Typhi causes a restrained immune response in the 
host. Lower levels of  IL-1β and TNF-α production by T- and B-cells compared to 
other Gram-negative bacteria infections during the acute phase of typhoid fever has 
been observed (Tsolis et al., 2008). This result in limited neutrophil influx and explains 
why S. Typhi typically does not elicit septic shock and have prolonged incubation 
period (Gal-Mor et al., 2012). As S. Typhi continues to multiply and induce 
macrophage apoptosis, the bacteria breaks out into the bloodstream, leading to the start 
of the humoral immune response. 
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1.2.3 (bii) Humoral Immune Response 
Humoral immune response involves B cells which proliferate and differentiate into 
plasma cells and produce specific antibodies to neutralise and induce phagocytosis to 
destroy the bacteria. This immune response is important especially when S. Typhi is 
at the extracellular stage. 
 
S. Typhi possess 3 main antigens; (1) somatic antigen O, (2) flagellar antigen H, and 
(3) surface antigen Vi. Antigenic structure of S. Typhi is shown in Figure 1.4. O, H 
and Vi antigens are the most studied activator of B cells to orchestrate the typhoid 
humoral immune response (Waddington et al., 2014). O antigen is made up of 
polysaccharide and occurs on the surface of the outer membrane of the bacteria. It 
displays variable structures which are recognized by the humoral immune system 
leading to various Salmonella serovars (Liu et al., 2014). H antigen constitutes the 
flagella, which is essential for attachment and invasion of the host intestinal epithelial 
cells, and also in biofilm formation (Haiko & Westerlund-Wikström, 2013). H antigen 
exists in 2 phases, called phase 1 and phase 2. Some Salmonella serotypes express one 
phase of H antigen (monophasic). Some others express both phases (diphasic). Some 
Salmonella serovars tend to change from one phase to another, which is termed as 
“phase variation”. Vi antigen is a capsular polysaccharide antigen located on the 
surface of the bacteria, and is associated with S. Typhi virulence. It also plays a main 
role in preventing S. Typhi from being phagocytized by macrophages(Janis et al., 
2011). However, Vi antigen is not essential for S. Typhi infection as Vi-negative 
mutants of S. Typhi can still cause typhoid fever (Pulickal et al., 2013). Reliance of Vi 
antigen for serological testing will result in poor prognosis. 
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Antibodies against these S. Typhi antigens could be found in serum and other 
secretions.  However, this humoral immune response does not confer long-life 
protection, but, instead, relapse of typhoid fever has been observed in 15–20% of 
individuals who had recovered from previous typhoid fever infection (Guzman et al., 
2006). Anti-O, -H and -Vi antibodies have been widely used as targets in various 
diagnostic tests, e.g. Widal (Olopoenia & King, 2000; Andualem et al., 2014),  
enzyme-linked immunosorbent assay (ELISA) (Fadeel et al., 2004) and Tubex® 
(Khanna et al., 2015) tests. 
 
Humoral immune response of typhoid fever is not restricted to O, H and Vi antigens. 
Ty21a vaccine which is an attenuated S. Typhi live bacteria lack Vi antigen, gives 
similar protection with that of purified Vi capsular polysaccharide subunit (ViCPS) 
vaccine (Kantele et al., 2012). These observations show that multiple adaptive immune 
response mechanisms are involved in eliminating the bacteria from the host. Although 
the humoral response in typhoid infection is mainly defined by the O, H and Vi 
antigens, there are other antigens such as the outer membrane proteins and heat shock 
proteins which have been shown to elicit specific antibody production (Sztein, 2007). 
However, these proteins have not been studied in detail. 
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1.2.3 (biii) Important Antibody Isotypes in Typhoid Serology 
The initial exposure to S. Typhi causes the immune system to produce IgM. It activates 
the complement system by the Classical Pathway, promoting phagocytosis and 
destruction of the microbe. During S. Typhi infection, the level of IgM is detectable as 
early as 5-7 days of infection. Typhoid patients generally show significant rise in 
serum IgM titres during the first 10 days of illness and persists only for 45-90 days 
after acute illness, while serum IgG dominates the convalescent phase and can persist 
for more than 2 years after typhoid infection (Herath, 2003). IgM is therefore more of 
diagnostic significance than IgG to differentiate between acute and convalescent cases 
in an endemic population. 
 
IgG functions in a variety of ways including opsonisation of antigen, complement 
activation, and neutralisation of pathogen. IgG production is induced by IFN-γ which 
responses to S. Typhi infection. IgG persists longer than IgM and can have a half-life 
of more than 2 years after typhoid infection (Ismail, 2000). Thus, it is not suitable to 
be used for diagnosis of typhoid fever in highly endemic areas. Approximately 80% 
of S. Typhi chronic carriers manifest high titres of serum IgG against S. Typhi Vi 
antigen (Vaishnavi et al., 2005). Thus, anti-Vi IgG has been routinely utilised for 
screening of chronic carriers (Sztein et al., 2014). It is, however, unlikely to be 
effective in endemic regions as false-positive results may be obtained in acute or 
convalescent cases (House et al., 2008). 
 
IgA is secreted in mucosal tissues and neutralises microbes including those in the 
lumens of the gastrointestinal and respiratory tracts, preventing adherence of the 
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bacteria to epithelial cells and therefore gives protection to the mucosa. Increased IgA 
titres in typhoid patients’ saliva have been observed during the first and second weeks 
of illness (Herath, 2003), and therefore has diagnostic uses (Zeeba Zaka-ur-Rab et al., 
2012; Herath, 2003; Chin et al., 2016). 
 
1.2.4 Clinical Features 
The incubation period of the infection is typically between 7-14 days (Bhutta, 2006a). 
Typhoid fever generally produces indistinguishable clinical features from other febrile 
diseases such as malaria, leptospirosis, dengue and tuberculosis. The hallmark of 
typhoid fever is prolonged fever, which could increase daily in a stepwise manner to 
as high as 38-40°C in the third or fourth day of illness (WHO, 2003). Other symptoms 
include mild abdominal discomfort, headache, malaise, loss of appetite, constipation 
or diarrhoea, hepatomegaly and splenomegaly. In certain cases, transient rash of rose-
coloured spots in the abdomen can be observed. Serious complications such as 
intestinal perforation, intestinal haemorrhage and typhoid encephalopathy occur 
between 10-15% of patients, sometimes with lethal consequences (Basnyat et al., 
2005). Factors which influence the severity of the infection include the status of host’s 
immune system, the infecting dose of the bacteria, history of vaccination, medication, 
and virulence of the bacteria strains  (Bhutta, 2006a). Patients with immune-
suppressed conditions are of greater risk of developing the disease with greater 
morbidity and mortality rates. 
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1.2.5 Typhoid Carrier State 
Approximately 1-5% of acute typhoid patients become chronic carriers (WHO, 2003). 
Carriers are individuals who harbour S. Typhi in their gallbladder, and excrete them in 
stool or urine, without showing any symptoms. S. Typhi stays innocuous in carriers, 
but poses a “silent” threat to the community, sometime causing outbreaks of typhoid 
fever in the population. 
 
The predisposing factor for development of the carrier state is that of the ability of 
certain strains of S. Typhi which are resistant to bile by forming biofilm in the 
gallbladder. The biofilm layer overcomes the action of antimicrobial agents, such as 
antibiotics, disinfectants and preservatives (Marathe et al., 2012), allowing it to be 
sequestered in the gallbladder or kidneys without being detected by the host immune 
system. The propensity to become a carrier was reported to be higher in females 
especially those who are greater than 50 years old and persons with cholelithiasis or 
schistosomiasis (Bhan et al., 2005; Ja’afar et al., 2013). 
 
Generally, carriers are divided into 3 categories based on the S. Typhi excretion period: 
i) convalescent carriers, who continue to excrete S. Typhi 3 weeks to 3 months after 
the acute illness; ii) temporary carriers, who continue to excrete S. Typhi between 3-
12 months after the acute illness; and iii) chronic carriers who continue to excrete S. 
Typhi for more than 1 year after the acute illness. Approximately 1-5% of typhoid 
patients become chronic carriers after recovering from the acute illness. The 
occurrence of typhoid fever outbreaks is often associated with asymptomatic carriers, 
particularly those who work as food-handlers (Gupta et al., 2006). If the carriers could 
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not be identified, further spreading of the disease will occur, adding more difficulties 
in the control of the disease. Therefore, identification of typhoid carriers and extensive 
antibiotic treatment for this group of people, is extremely important. However, there 
is currently no reliable laboratory diagnostics for identification of typhoid carriers. 
Stool culture, which remains the gold standard for identification of carriers, only has 
a recovery rate of 5%, owing to intermittent secretion of S. Typhi from the carriers 
(Ismail, 2000). As such, identification of typhoid carriers remains challenge and an 
obstacle for eradication of the disease. 
 
Perhaps, the most notorious typhoid carrier was Mary Malloon or better known as 
“Typhoid Marry”. Her career as a cook in New York city become one of the main 
route for spreading the disease among customers, families or friends. Eventually, 51 
typhoid fever victims and 3 deaths were traced to her. She was forcibly taken into 
custody twice in her life by local health officials, and was detained until she die at the 
age of 69 (Marineli et al., 2013). 
 
1.2.6 Treatment of Typhoid Fever - Antibiotic Therapy 
Typhoid fever can be controlled by antibiotic therapy. With the advent of pre-emptive 
antibiotic treatment, 99% of typhoid cases survival could be assured. However, 
without effective treatment, typhoid fever may progress to more severe illness, such 
as peritonitis, intestinal haemorrhage or perforation, leading to fatality in 10-30% of 
cases (Buckle et al., 2012). 
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The selection of antibiotics depends on the clinical severity and antimicrobial 
susceptibility test. As per the WHO recommendation, the primary antibiotic treatment 
for S. Typhi infection is fluoroquinolones, followed by nalidixic acid and other 
antimicrobial agents. Fluoroquinolones such as ciprofloxacin, ofloxacin and 
pefloxacin are widely regarded as the ideal antibiotic of choice for typhoid fever 
(Upadhyay et al., 2015; WHO, 2003). They demonstrate excellent ability to penetrate 
tissues and destroy the S. Typhi in monocytic cells such as macrophages, leading to 
rapid therapeutic response. 
 
In the past decades, drug-resistant S. Typhi strains have emerged as a new threat. 
Fluoroquinolone-resistant strains have been reported in several countries, such as 
Nepal and India (Nobthai et al., 2010; Dutta et al., 2008; Afzal et al., 2012). For these 
isolates, the use of ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole 
is recommended. In the mid 1980’s, antimicrobial treatment has become more difficult 
with the emergence of pHCM1 plasmid-mediated multidrug-resistant strains, which 
are resistant to all 3 first-line antimicrobial agents, including chloramphenicol, 
ampicillin and trimethoprim-sulfamethoxazole (Zaki & Karande, 2011). In these cases, 
third-generation cephalosporins, such as ceftriaxone or cefotaxime are recommended 
(Zaki & Karande, 2011; Bhutta, 2006a). The selection of antibiotics based on the 
clinical severity and drug susceptibility of the S. Typhi strain is shown in Table 1.2.
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Table 1.2 Recommended treatment of uncomplicated typhoid fever adapted from WHO technical communities (Bhutta, 2006b; WHO, 2003)  
 
Susceptibility 

















Chloramphenicol 50-75 14-21 
Amoxicillin 75-100 14 
TMP-SMX 8-40 14 
Multidrug resistance 
Fluoroquinolone 15 5-7 Azithromycin 8-10 7 
cefixime 15-20 7-14 Cefixime 15-20 7-14 
Quinolone 
resistanceb 
Azithromycin 8-10 7 
Cefixime 20 7-14 
ceftriaxone 75 10-14 





Chloramphenicol 100 14-21 
Ampicilin 100 14 
TMP-SMX 8/40 14 






10-14 Fluoroquinolone 20 14 
cefotaxime 80 
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1.2.7 Prevention of Typhoid Fever 
Recognising the threat posed by typhoid fever epidemics, strategies for prevention and 
control of this disease are urgently needed. Some approaches to reduce typhoid fever 
burden include vaccination, appropriate surveillance systems, safe water supply, 
improved sanitation facilities, rational use of antibiotics, appropriate personal hygiene 
and public health education. For government to regulate resources for these purposes, 
accurate figures of the disease burden is essential. However, lack of adequate 
diagnostic tools forms the formidable obstacle to estimate the true disease burden. 
 
1.2.7 (a) Vaccines 
Immunisation is one of the keys to prevent and control of the disease. At present, there 
are 3 licensed typhoid vaccines available: 1) whole cell live attenuated S. Typhi 
(Ty21a) oral vaccines; 2) purified Vi capsular polysaccharide subunit (ViCPS) vaccine 
(Shawky Hosny et al., 2015), and 3) Vi-conjugate vaccine. 
 
Ty21a vaccine is licensed for persons aged older than 6 years and requires 3 to 4 doses 
oral administration on alternating days. It induces both cell-mediated and humoral 
immunity. It is available in both liquid and coated capsule forms (Marathe et al., 2012). 
As a live attenuated vaccine, it should not be administered to immune-compromised 
persons or persons having antibiotic treatment. 
 
ViCPS vaccine is recommended by WHO as the vaccine of choice for typhoid fever 
as it is free from endotoxin and requires only a single dose for effective immunity. In 
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addition, it is also suitable for children over 2 years old, individuals receiving antibiotic 
therapy and immune-compromised individuals (Shawky Hosny et al., 2015). This 
vaccine confers 50-80% protection against typhoid fever (Anwar et al., 2014). 
 
The present available vaccines are not suitable for mass immunisation, especially to 
children less than 2 years old and the elderly. Continuous efforts are being made to 
develop vaccines which can provoke higher antibody titres and longer immunity with 
reduced side effects. A new Vi antigen which is conjugated to exotoxin A (rEPA) of 
pseudomonas aeruginosa vaccine (Vi-rEPA) has been developed (Szu, 2013). This 
vaccine showed enhanced immunogenicity in adults and children compared to Vi 
antigen alone (Jin et al., 2017). Remarkably, it protects most of the recipients in trials 
including children below the age of 5. 
 
Although effective vaccines are available, there is no plan for vaccination programme 
for infants and children. Some do not trust the vaccine, claiming the side effects of 
vaccine pose a greater health risk than the disease itself. Out of 16 Asia countries where 
typhoid is endemic, only 3 countries, i.e. India, Vietnam and Thailand have allowed 
mass immunisation to protect their child (Ochiai et al., 2007). The main cause of this 
neglect is due to the inadequacies of routine diagnostics which generally make the 
disease burden somewhat uncertain. All these form a major obstacle in the control and 




1.3 Diagnosis of Typhoid Fever 
Typhoid fever typically produces similar clinical features as with other febrile 
diseases, such as malaria, leptospirosis and dengue. Due to non-specific clinical 
manifestations, laboratory testing is therefore essential for typhoid fever diagnosis. 
Diagnostic methods used in diagnosis of typhoid fever include: (1) blood or stool 
bacterial culture method following phenotypic identification using biochemical and 
serotyping assays; (2) detection of antigens or antibodies by immunological assays, 
and (3) detection of DNA or proteins by molecular assays (Lee et al., 2015). The 
choice of diagnostic methods depends on the laboratory facilities, budget and nature 
of the test samples. Presently, diagnosis of typhoid fever under the gold standard 
method ISO 6579:2002 (International Organization for Standardization, 2002) is 
through isolation of the bacteria from blood and stool samples, followed by 
biochemical and serological tests. However, these methods are time-consuming and 
laborious, delaying appropriate disease treatment and containment (Parry et al., 2011). 
 
1.3.1 Culture Systems 
S. Typhi clinical strains can be isolated from blood, stool, urine, bone marrow, 
duodenal fluid and saliva of patients (Herath, 2003; Z. Zaka-ur-Rab et al., 2012). The 
diagnostic efficacy of the culture method differs with the specimens tested. The highest 
recovery rate (detection rate) of S. Typhi is from bone-marrow, followed by blood, 
stool and urine in patients with typhoid fever (Mogasale et al., 2016) 
. 
 
